Global X Genomics & Biotechnology ETF
GNOM
64 hedge funds and large institutions have $121M invested in Global X Genomics & Biotechnology ETF in 2022 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 11 increasing their positions, 28 reducing their positions, and 5 closing their positions.
2,900% more call options, than puts
Call options by funds: $30K | Put options by funds: $1K
160% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 5
10% more funds holding
Funds holding: 58 → 64 (+6)
0.39% less ownership
Funds ownership: 16.27% → 15.88% (-0.39%)
10% less capital invested
Capital invested by funds: $134M → $121M (-$13.3M)
61% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lido Advisors
Los Angeles,
California
|
+$4.15M |
| 2 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
+$1.99M |
| 3 |
Jane Street
New York
|
+$491K |
| 4 |
OCM
One Capital Management
Westlake Village,
California
|
+$397K |
| 5 |
Stifel Financial
St. Louis,
Missouri
|
+$309K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIG
McGuire Investment Group
Wakefield,
Rhode Island
|
-$3.43M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$2.3M |
| 3 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
-$1.74M |
| 4 |
MML Investors Services
Springfield,
Massachusetts
|
-$480K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$387K |
GNOM Hedge Fund Activity: Q4 2022 in Review
64 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Global X Genomics & Biotechnology ETF (GNOM) for Q4 2022, worth a combined $121M — down 9.9% from $134M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new GNOM positions and 5 closed out — a net gain of 8 holders — while 11 added to existing stakes and 28 trimmed.
The largest buyer was Lido Advisors, opening a new position worth an estimated $4.15M. The largest seller was McGuire Investment Group, cutting an estimated $3.43M.
- 64 institutional investors held Global X Genomics & Biotechnology ETF (GNOM) as of Q4 2022, up from 58 in Q3 2022.
- Funds reported $121M of Global X Genomics & Biotechnology ETF stock for Q4 2022, down 9.9% quarter-over-quarter.
- 13 funds opened new Global X Genomics & Biotechnology ETF positions in Q4 2022 and 5 closed out, a net change of +8 holders.
- The largest Global X Genomics & Biotechnology ETF buyer in Q4 2022 was Lido Advisors, an estimated $4.15M added.
- The largest Global X Genomics & Biotechnology ETF seller in Q4 2022 was McGuire Investment Group, an estimated $3.43M sold.
Based on aggregated 13F filings for Q4 2022.